A Texas judge has finalized a $158 million settlement between Texas and a subsidiary of health care giant Johnson & Johnson in a Medicaid fraud lawsuit over the anti-psychotic drug Risperdal.
The agreement, reached during a January trial settled a lawsuit that accused J&J and its subsidiaries of fraud by false or misleading statements about the safety, cost and effectiveness of the drug.
The settlement was approved during a court hearing Tuesday in Austin.
The whistleblower lawsuit was filed by Allen Jones. His attorney, Tom Melsheimer, said Texas will get 40 percent of the settlement; the federal government gets 31 percent; Jones gets 17 percent; and 12 percent goes to attorneys’ fees.
The health care giant has said it’s not admitting fault with the settlement.
Topics Lawsuits Texas Legislation
Was this article valuable?
Here are more articles you may enjoy.
The Hartford Q3 Net Income Up 41% 
Progressive Now 4th Largest Global Insurer; RenRe Fastest Growing in ’24 
Alaska Airlines Vows IT Upgrades After Outage Forces 400 Flight Cancellations 
Brown & Brown Reports Strong Q3 Revenue Growth of 35.4% 
